Type 2 Diabetes Mellitus, Weight Loss
Conditions
Brief summary
This study was a single-center, single-dose, open-label study in healthy male subjects to investigate the absorption, metabolism and excretion of HRS9531 after a single subcutaneous injection of \[14C\]HRS9531.
Interventions
DRUG[14C]HRS9531
A single dose of \[14C\]HRS9531 injected subcutaneously.
Sponsors
Fujian Shengdi Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Sign the informed consent form prior to the trial and have a full understanding of the trial's procedures, content and potential adverse reactions. 2. Healthy male subjects aged between 18 and 55 years (inclusive), determined at the time of signing the informed consent. 3. Body weight ≥50 kg, and the body mass index (BMI) between 19 to 32.5 kg/m2. 4. From the signing of the informed consent form until 12 months after the last administration, the subject (including partner) has no family planning and is willing to use the high-efficiency contraceptive measures specified in the plan.
Exclusion criteria
1. History of any clinically important disease or disorder. 2. History of drug or other allergies, or who, in the judgement of the investigator, may be allergic to the study drug or any component of the study drug. 3. Physical examination, vital signs or other laboratory measurements, other electrocardiographic parameters, abdominal ultrasound (except mild fatty liver), and abnormalities on chest radiography as judged by the investigator to be clinically significant. 4. The subject was considered by the investigator to have any other factors that would preclude him from participating in the study or the subject withdrew from the study due to his own reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative radioactive recovery rate in feces. | 0 to anticipated 64 days. |
| Half-life (t1/2). | 0 to anticipated 64 days. |
| Total radioactive recovery rate in urine. | 0 to anticipated 64 days. |
| Total radioactive recovery rate in feces. | 0 to anticipated 64 days. |
| Cumulative radioactive recovery rate in urine. | 0 to anticipated 64 days. |
| Maximum concentration (Cmax). | 0 to anticipated 64 days. |
| Time to reach the maximum concentration (Tmax). | 0 to anticipated 64 days. |
Secondary
| Measure | Time frame |
|---|---|
| Plasma total radioactivity (TRA) ratio. | 0 to anticipated 64 days. |
| Adverse events (AEs). | 0 to 7 days after the last sample collection. |
| Serious adverse events (SAEs). | 0 to 7 days after the last sample collection. |
| Whole blood total radioactivity (TRA) ratio. | 0 to anticipated 64 days. |
Countries
China
Outcome results
None listed